123 related articles for article (PubMed ID: 34789057)
1. Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis.
Khanal N; Shostrom V; Dhakal P; Upadhyay Banskota S; Chaulagain C; He F; Mosalpuria K; Gundabolu K; Bhatt VR
Leuk Lymphoma; 2022 Apr; 63(4):939-945. PubMed ID: 34789057
[TBL] [Abstract][Full Text] [Related]
2. Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: A National Cancer Database Study.
Bhatt VR; Chen B; Lee SJ
Bone Marrow Transplant; 2018 Jul; 53(7):873-879. PubMed ID: 29403021
[TBL] [Abstract][Full Text] [Related]
3. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV
Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234
[TBL] [Abstract][Full Text] [Related]
4. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
[TBL] [Abstract][Full Text] [Related]
5. Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis.
Konuma T; Harada K; Yamasaki S; Mizuno S; Uchida N; Takahashi S; Onizuka M; Nakamae H; Hidaka M; Fukuda T; Ohashi K; Kohno A; Matsushita A; Kanamori H; Ashida T; Kanda J; Atsuta Y; Yano S;
Am J Hematol; 2019 Jan; 94(1):103-110. PubMed ID: 30370944
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia.
Dhakal P; Shostrom V; Al-Kadhimi ZS; Maness LJ; Gundabolu K; Bhatt VR
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):804-812.e8. PubMed ID: 32739312
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
8. Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults.
Min GJ; Kim HJ; Yoon JH; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1621-1628. PubMed ID: 29698793
[TBL] [Abstract][Full Text] [Related]
9. Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia.
Wass M; Hitz F; Schaffrath J; Müller-Tidow C; Müller LP
PLoS One; 2016; 11(10):e0164587. PubMed ID: 27732646
[TBL] [Abstract][Full Text] [Related]
10. Early mortality and overall survival of acute myeloid leukemia based on facility type.
Bhatt VR; Shostrom V; Giri S; Gundabolu K; Monirul Islam KM; Appelbaum FR; Maness LJ
Am J Hematol; 2017 Aug; 92(8):764-771. PubMed ID: 28437868
[TBL] [Abstract][Full Text] [Related]
11. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML).
Tawfik B; Pardee TS; Isom S; Sliesoraitis S; Winter A; Lawrence J; Powell BL; Klepin HD
J Geriatr Oncol; 2016 Jan; 7(1):24-31. PubMed ID: 26527394
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and outcomes of elderly patients with acute myeloid leukemia who receive no treatment in the Surveillance, Epidemiology and End Results-Medicare database.
Dharmani C; Wang E; Tu N; Salas M; Kamel YM
Future Oncol; 2023 Jan; 19(2):159-171. PubMed ID: 36912693
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.
Sorror ML; Storer BE; Fathi AT; Gerds AT; Medeiros BC; Shami P; Brunner AM; Sekeres MA; Mukherjee S; Peña E; Elsawy M; Wardyn S; Whitten J; Moore R; Becker PS; McCune JS; Appelbaum FR; Estey EH
JAMA Oncol; 2017 Dec; 3(12):1675-1682. PubMed ID: 28880971
[TBL] [Abstract][Full Text] [Related]
14. Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy.
Bhatt VR; Shostrom V; Holstein SA; Al-Kadhimi ZS; Maness LJ; Berger A; Armitage JO; Gundabolu K
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):e239-e258. PubMed ID: 32111572
[TBL] [Abstract][Full Text] [Related]
15. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
[TBL] [Abstract][Full Text] [Related]
16. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia.
Schneidawind C; Hagmaier V; Faul C; Kanz L; Bethge W; Schneidawind D
Ann Hematol; 2018 Dec; 97(12):2491-2500. PubMed ID: 30066039
[TBL] [Abstract][Full Text] [Related]
17. Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission.
Usuki K; Kurosawa S; Uchida N; Yakushiji K; Waki F; Matsuishi E; Kagawa K; Furukawa T; Maeda Y; Shimoyama M; Ago H; Yamano Y; Yano S; Fujishima N; Takamatsu Y; Eto T; Hidaka M; Matsuoka H; Fukuda T
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):444-51. PubMed ID: 22999942
[TBL] [Abstract][Full Text] [Related]
18. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years.
Major CK; Kantarjian H; Sasaki K; Borthakur G; Kadia T; Pemmaraju N; DiNardo C; Short NJ; Daver N; Jabbour E; Champlin R; Garcia-Manero G; Konopleva M; Andreeff M; Kornblau S; Wierda W; Pierce S; Ravandi F; Cortes J
Leuk Lymphoma; 2020 Dec; 61(13):3120-3127. PubMed ID: 32755333
[TBL] [Abstract][Full Text] [Related]
19. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
[TBL] [Abstract][Full Text] [Related]
20. Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients.
Jabo B; Morgan JW; Martinez ME; Ghamsary M; Wieduwilt MJ
PLoS One; 2017; 12(4):e0174760. PubMed ID: 28384176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
